Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment?

dc.contributor.authorM Pietilä
dc.contributor.authorJ Ivaska
dc.contributor.authorSA Mani
dc.contributor.author
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.contributor.organization-code2609201
dc.converis.publication-id17185381
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/17185381
dc.date.accessioned2022-10-28T13:27:10Z
dc.date.available2022-10-28T13:27:10Z
dc.description.abstractChanges in the tumor microenvironment (TME) can trigger the activation of otherwise non-malignant cells to become highly aggressive and motile. This is evident during initial tumor growth when the poor vascularization in tumors generates hypoxic regions that trigger the latent embryonic program, epithelial-to-mesenchymal transition (EMT), in epithelial carcinoma cells (e-cars) leading to highly motile mesenchymal-like carcinoma cells (m-cars), which also acquire cancer stem cell properties. After that, specific bidirectional interactions take place between m-cars and the cellular components of TME at different stages of metastasis. These interactions include several vicious positive feedback loops in which m-cars trigger a phenotypic switch, causing normal stromal cells to become pro-tumorigenic, which then further promote the survival, motility, and proliferation of m-cars. Accordingly, there is not a single culprit accounting for metastasis. Instead both m-cars and the TME dynamically interact, evolve and promote metastasis. In this review, we discuss the current status of the known interactions between m-cars and the TME during different stages of metastasis and how these interactions promote the metastatic activity of highly malignant m-cars by promoting their invasive mesenchymal phenotype and CSC properties. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
dc.format.pagerange359
dc.format.pagerange368
dc.identifier.jour-issn0304-3835
dc.identifier.olddbid182180
dc.identifier.oldhandle10024/165274
dc.identifier.urihttps://www.utupub.fi/handle/11111/39335
dc.identifier.urnURN:NBN:fi-fe2021042715626
dc.language.isoen
dc.okm.affiliatedauthorPietilä, Mika
dc.okm.affiliatedauthorIvaska, Johanna
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherELSEVIER IRELAND LTD
dc.publisher.countryIrelanden_GB
dc.publisher.countryIrlantifi_FI
dc.publisher.country-codeIE
dc.relation.doi10.1016/j.canlet.2015.12.033
dc.relation.ispartofjournalCancer Letters
dc.relation.volume380
dc.source.identifierhttps://www.utupub.fi/handle/10024/165274
dc.titleWhom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment?
dc.year.issued2016

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Pietila et al. Cancer letter.pdf
Size:
582.94 KB
Format:
Adobe Portable Document Format